Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
| ▸ | CCKAR | P32238 | 7/20 | 0.40 |
| ▸ | CCKBR | P32239 | 7/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7953485 | 1.00 | GLP1R (0.55) | GLP1RFOLH1CCKARCCKBRGLO1 | |
| SCHEMBL15428776 | 1.00 | GLP1R (0.55) | GLP1RFOLH1CCKARCCKBRGLO1 | |
| SCHEMBL18379187 | 1.00 | GLP1R (0.55) | GLP1RFOLH1CCKARCCKBRGLO1 | |
| SCHEMBL7947055 | 1.00 | GLP1R (0.55) | GLP1RFOLH1CCKARCCKBRGLO1 | |
| SCHEMBL2151921 | 1.00 | GLP1R (0.55) | GLP1RFOLH1CCKARCCKBRGLO1 | |
| SCHEMBL20608169 | 1.00 | GLP1R (0.55) | GLP1RFOLH1CCKARCCKBRGLO1 | |
| SCHEMBL12276299 | 1.00 | GLP1R (0.55) | GLP1RFOLH1CCKARCCKBRGLO1 | |
| SCHEMBL12275938 | 1.00 | GLP1R (0.55) | GLP1RFOLH1CCKARCCKBRGLO1 | |
| SCHEMBL1893405 | 1.00 | GLP1R (0.55) | GLP1RFOLH1CCKARCCKBRGLO1 | |
| SCHEMBL2435629 | 1.00 | GLP1R (0.55) | GLP1RFOLH1CCKARCCKBRGLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421289-B2 | GLP-1 analogues | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2025-09-23 | — | — | US | disclosed |
| CN-119978139-A | Fusion polypeptide and method for preparing target polypeptide by using same | 浙江泽瑞生物医药有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-106139158-B | Growth hormone with prolonged in vivo efficacy | 诺沃—诺迪斯克保健股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240199718-A1 | GLP-1 Analogues | SUN PHARMACEUTICAL IND LTD (IN) | 2024-06-20 | — | — | US | disclosed |
| EP-4364751-A2 | NOVEL GLP-1 ANALOGUES | Sun Pharmaceutical Industries Limited (IN) | 2024-05-08 | — | — | EP | disclosed |
| EP-4122954-B1 | NOVEL GLP-1 ANALOGUES | SUN PHARMACEUTICAL IND LTD (IN) | 2024-04-03 | — | — | EP | disclosed |
| US-11873328-B2 | GLP-1 analogues | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2024-01-16 | — | — | US | disclosed |
| US-11866477-B2 | GLP-1 analogues | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2024-01-09 | — | — | US | disclosed |
| US-20230364248-A1 | MIC-1 COMPOUNDS AND USES THEREOF | NOVO NORDISK AS (DK) | 2023-11-16 | — | — | US | disclosed |
| US-11787837-B2 | DCHBS-active esters of PEG compounds and their use | NOVO NORDISK A/S (DK) | 2023-10-17 | — | — | US | disclosed |
| WO-2011101277-A1 | CONJUGATED PROTEINS | NOVO NORDISK A/S (DK) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011089255-A1 | GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY | NOVO NORDISK HEALTH CARE AG (CH) | 2011-07-28 | — | — | WO | disclosed |
| EP-2340049-A1 | METHOD OF ACYLATING A PEPTIDE OR PROTEIN | Novo Nordisk A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| WO-2010142665-A1 | GLP-1 AND FGF21 COMBINATIONS FOR TREATMENT OF DIABETES TYPE 2 | NOVO NORDISK A/S (DK) | 2010-12-16 | — | — | WO | disclosed |
| US-20100317057-A1 | SEMI-RECOMBINANT PREPARATION OF GLP-1 ANALOGUES | NOVO NORDISK A/S (DK) | 2010-12-16 | — | — | US | disclosed |
| US-20100216715-A1 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use | NOVO NORDISK A/S (DK) | 2010-08-26 | — | — | US | disclosed |
| WO-2010084169-A2 | FGF21 DERIVATIVES WITH ALBUMIN BINDER A-B-C-D-E- AND THEIR USE | NOVO NORDISK A/S (DK) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010084169-A2 | FGF21 DERIVATIVES WITH ALBUMIN BINDER A-B-C-D-E- AND THEIR USE | NOVO NORDISK A/S (DK) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010029159-A1 | METHOD OF ACYLATING A PEPTIDE OR PROTEIN | NOVO NORDISK A/S (DK) | 2010-03-18 | — | — | WO | disclosed |
| WO-2009083549-A1 | SEMI-RECOMBINANT PREPARATION OF GLP-1 ANALOGUES | NOVO NORDISK A/S (DK) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216715-A1 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use | FABP1, FABP4, FGFR1 | GLP1R 45/4885FOLH1 1037/4885CCKAR 729/4885 |
| US-20230364248-A1 | MIC-1 COMPOUNDS AND USES THEREOF | IMMT, MICA, TAP1 | GLP1R 710/4885FOLH1 1511/4885CCKAR 1112/4885 |
| US-12421289-B2 | GLP-1 analogues | GLP1R, GIPR, GPR119 | GLP1R 1/4885FOLH1 508/4885CCKAR 30/4885 |
| US-20240199718-A1 | GLP-1 Analogues | GLP1R, GIPR, GPR119 | GLP1R 1/4885FOLH1 508/4885CCKAR 30/4885 |
| US-11873328-B2 | GLP-1 analogues | GLP1R, GIPR, GPR119 | GLP1R 1/4885FOLH1 508/4885CCKAR 30/4885 |
| US-11866477-B2 | GLP-1 analogues | GLP1R, GIPR, GPR119 | GLP1R 1/4885FOLH1 508/4885CCKAR 30/4885 |
| US-11787837-B2 | DCHBS-active esters of PEG compounds and their use | HBB, IAPP, GLP1R | GLP1R 3/4885FOLH1 2215/4885CCKAR 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.